FDA
-
-
-
-
-
-
-
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
-
-
-
-
-
-
-
Cyclo Therapeutics (CYTH) Reports Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol Cyclo
-
-
-
-
-
-
-
Cyclo Therapeutics (CYTH) Reports FY 21 Results, Provides Business Update
-
-
-
-
-
-
-
Cyclo Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
-
-
-
-
-
-
-
Cyclo Therapeutics Commences Patient Enrollment in TransportNPC, a Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
-
-
-
-
-
-
-
Cyclo Therapeutics (CYTH) Receives Positive Opinion from Paediatric Committee of EMA on Agreement of Paediatric Investigation Plan for Trappsol Cyclo
-
-
-
-
-
322,094 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

